Home Biotechnology Coherus Oncology
C

Coherus Oncology

Profile managed by Bizz Id
United States

Description

Coherus Oncology (Coherus BioSciences) is a commercial-stage biopharmaceutical company focused on immuno-oncology. It markets the anti-PD-1 antibody Loqtorzi (toripalimab-tpzi) in the US and develops antibodies targeting the tumour microenvironment (anti-CCR8 and anti-IL-27).

Products

3 products
Casdozokitug

IL-27 antagonist monoclonal antibody. Phase 2 (1L hepatocellular carcinoma, with toripalimab + bevacizumab).

Under development

Finished product (FDF)

Verified on 2026-10-21

Casdozokitug: see suppliers →

Tagmokitug

Anti-CCR8 monoclonal antibody. Phase 2 (4L+ colorectal cancer, with toripalimab); Phase 1 in other solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

Tagmokitug: see suppliers →

Toripalimab

Brand: LOQTORZI (toripalimab-tpzi). Anti-PD-1 monoclonal antibody. Nasopharyngeal carcinoma: 1L with chemotherapy and 2L+ monotherapy. Immuno-oncology.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Toripalimab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free